1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Alsomairy

Examiner Alsomairy Sarah A

1646-ALSOMAIRY-SARAH-A

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
702 — Data processing: measuring, calibrating, or testing
536 — Organic compounds -- part of the class 532-570 series
706 — Data processing: artificial intelligence
Phone:(571) 272-0027
Email:sarah.alsomairy@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:5 years
Grade:GS-12

Grant Rate and Difficulty Ranking

91
3-Year Grant rate: 29% over 140 cases
Difficulty: Extremely Hard
Difficulty Percentile: 91st

With Examiner Alsomairy, you have a 29% chance of getting an issued patent by 3 years after the first office action. Examiner Alsomairy is an extremely hard examiner and in the 91st percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Alsomairy, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Alsomairy's grant rate is lower than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Alsomairy 1.5
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Alsomairy has granted 34 of 130 cases without any applicant-requested interviews for a grant rate of 26%.

Grant Rate with Interview

Examiner Alsomairy has granted 6 of 10 cases with at least one applicant-requested interview for a grant rate of 60%.

Interview Benefit

With Examiner Alsomairy, conducting an interview increases your chance of getting a patent granted by 131%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18342322 Prostate Neoantigens And Their Uses Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18503865 Role Of Pvt1 In The Diagnosis And Treatment Of Myc-Driven Cancer Patented View
18402252 Fibroblast Binding Agents And Use Thereof Patented View
17413881 Antibodies To Misfolded Tdp-43 And Methods Of Use Patented View
17411158 Treatment Of Non-Small Cell Lung Cancer With Egfr Mutations Patented View
17312320 Herboxidiene Antibody-Drug Conjugates And Methods Of Use Patented View
18430961 Compositions And Methods For Modulating Cancer Immune Fitness Abandoned View
17747346 Methods For Identifying Cancer Patients For Combination Treatment Abandoned View
17771254 Compositions For Patient Specific Immunotherapy Abandoned View
17904953 Anti-Tumor Composition Abandoned View
17312419 Combination Therapy Of Arms And Natural Killer Cells Patented View
17626459 Chemically Controlled Monoclonal Antibody Target Engagement Patented View
17029361 Method For Assisting Determination Of Efficacy Of Immune Checkpoint Inhibitor Abandoned View
18322846 Targeting Intracellular Target-Binding Determinants With Intracellular Antibodies Patented View
17287838 Methods Of Treating Nsclc Comprising Administering Platinum Doublet Chemotherapy Followed By An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody Patented View
17586870 Methods Of Treating And Diagnosing Lung Cancer Abandoned View
17402329 Multifunctional Molecules That Bind To Calreticulin And Uses Thereof Abandoned View
17778677 Treatment Of Cancer With Anti-Ox40 Antibodies And Multi-Kinase Inhibitors Abandoned View
18510412 Combination Therapies With Bispecific Anti-Egfr/c-Met Antibodies And Third Generation Egfr Tyrosine Kinase Inhibitors Patented View
17624124 Sialidase-Her2-Antibody Fusion Proteins And Methods Of Use Thereof Abandoned View
17768484 Treatment Of Cancer With Ilt-2 Inhibitors Abandoned View
17314946 Bispecific Antibodies Against Cd3 And Cd20 Patented View
16816160 Methods Of Neoantigen Identification Patented View
19264065 Peptide-Hinge-Free Flexible Antibody-Like Molecule Abandoned View
18618414 Anti-Her2 Antibody Or Antigen-Binding Fragment Thereof, And Chimeric Antigen Receptor Comprising Same Patented View
17770039 Novel Anti-Cd47 Antibodies And Uses Thereof Patented View
17108771 Compositions And Methods Of Use Of Crispr-Cas Systems In Nucleotide Repeat Disorders Patented View
17471972 Tissue Based Rna In Situ Hybridization For Diagnosis And Treatment Selection In Dermatology Abandoned View
18415608 Heterodimeric Antibodies That Bind Prostate Specific Membrane Antigen (Psma) And Cd3 Patented View
17596442 Composition For Preventing Or Treating Cancer Abandoned View
17272791 Musk Inhibition Abandoned View
17560498 Novel Anti-Cd4o Antibodies And Use Thereof Abandoned View
16972724 Antigen Binding Constructs To Cd4 Patented View
18612767 Diagnostic Methods Using Anti-Muc1* Antibodies Patented View
18279671 Methods And Compositions For Treating Sepsis Abandoned View
17854739 Combination Of A Substance Modulating Tumor Immune Microenvironment And Immunotherapy For The Treatment Of Cancer Patented View
17422265 Anti-Beta 1 Integrin Humanized Antibody, And Pharmaceutical Composition For Treating Cancer, Comprising Same Patented View
18695836 Methods For Treating Atopic Dermatitis And Related Disorders Abandoned View
16837477 Anti-Cd73, Anti-Pd-L1 Antibodies And Chemotherapy For Treating Tumors Abandoned View
18286316 Methods And Compositions For Treating A Coronavirus Infection Abandoned View
18685172 Methods And Compositions For Reproductive Management Of Sheep And Goats Abandoned View
18254356 Methods Of Treating Liver Diseases Abandoned View
18267206 Biological Delivery Systems Abandoned View
18554273 Novel Lipocalin Muteins Specific For Connective Tissue Growth Factor (Ctgf) Abandoned View
18010081 Activatable Procytokines Abandoned View
17877020 Use Of Immune Checkpoint Inhibitors In Combination With Anti-Aging Drugs In Preparation Of Tumor Treatment Products Abandoned View
17610873 Dosage Regimes For The Administration Of A Lag-3/pd-L1 Bispecific Antibody Abandoned View
18056166 Methods Of Using Anti-Psgl-1 Antibodies In Combination With Jak Inhibitors To Treat T-Cell Mediated Inflammatory Diseases Or Cancers Patented View
17437179 Bio-Responsive Antibody Complexes For Enhanced Immunotherapy Abandoned View
17017942 Combination Therapy With Targeted 4-1bb (Cd137) Agonists Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.